RTP Mobile Logo
Second Opinion: Proceedings from an Interactive Case-Based Symposium on the Management of Patients with Metastatic Colorectal Cancer
Released July 2013

Proceedings from a CME symposium held at the 2013 ASCO Annual Meeting. Featuring perspectives from Drs Charles S Fuchs, Alan P Venook, Axel Grothey, Eric Van Cutsem and Tanios Bekaii-Saab. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologist-oncologists, gastrointestinal surgeons and other healthcare providers involved in the treatment of colorectal cancer (CRC).

    Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in both men and women in the United States. Because of the high incidence and lethality of the disease, extensive clinical research has been undertaken in an attempt to find better treatments and possible cures. Unfortunately, in the past 5 years these efforts have yielded little in terms of new systemic therapeutic options for this disease.

    However, an improved understanding of the biology of these tumors and the recent publication of several pivotal data sets have dramatically increased the collective enthusiasm that one day soon a number of new and effective therapies may be available to patients. To shed light on where we are and where we are headed with regard to the treatment of metastatic CRC (mCRC), these proceedings from a CME symposium at the 2013 ASCO Annual Meeting use the perspectives of clinical investigators to prepare clinicians for the impending introduction of potentially beneficial and exciting new strategies. By providing access to the latest research developments and expert opinions on this disease, this activity will assist medical oncologists and other healthcare providers in the formulation of up-to-date clinical management strategies for mCRC.


    • Apply clinical research data to optimize the use of anti-VEGF- and anti-EGFR-based therapy in the long-term management of advanced CRC.
    • Evaluate available research evidence with the use of regorafenib in mCRC, and identify potential patients in your practice for whom it might represent a reasonable nonprotocol option.
    • Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of mCRC.
    • Individualize local and systemic treatment for patients with mCRC that is isolated to the liver.
    • Recall new data with investigational agents demonstrating promising activity in CRC.
    • Educate patients with synchronous colon or rectal cancer and metastatic disease on the benefits and risks associated with available up-front treatment options.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles S Fuchs, MD, MPH
    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Sanofi.

    Alan P Venook, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Consulting Agreement: Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Onyx Pharmaceuticals Inc.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly USA LLC.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospital Gasthuisberg/Leuven
    Leuven, Belgium

    Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

    Tanios Bekaii-Saab, MD
    Section Chief, Gastrointestinal Oncology
    Chair, OSUCCC Gastrointestinal Disease Research Group
    Associate Professor of Medicine and Pharmacology
    The Ohio State University – James Cancer Hospital
    Columbus, Ohio

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Onyx Pharmaceuticals Inc, Sanofi; Data and Safety Monitoring Board: Polaris Group; Paid Research: Pfizer Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals and Genentech BioOncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Second Opinion: mCRC
Introduction: Dr Love
Module 1: Dr Fuchs Front-Line Treatment of mCRC
Module 2: Dr Venook Tx After Progression on Chemo/Bev
Module 3: Dr Grothey Regorafenib
Module 4: Prof Van Cutsem Potentially Resectable Liver Mets
Module 5: Dr Bekaii-Saab Synchronous Primary/ Metastatic Disease